Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | KJ Hamblett, SD Barnscher, RH Davies, PW Hammond, A Hernandez, GR Wickman, VK Fung, T Ding, G Garnett, AS Galey, P Zwierzchowski, BC Clavette, GC Winters, JR Rich, GJ Rowse, JS Babcook and D Hausman | ||||||||||||
Title | ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers | ||||||||||||
|
|||||||||||||
URL | https://cancerres.aacrjournals.org/content/79/4_Supplement/P6-17-13 | ||||||||||||
Abstract Text | Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ZW49 | ZW-49|ADC ZW49 | HER2 (ERBB2) Antibody 72 HER2 (ERBB2) Antibody-Drug Conjugate 27 | ZW49 is an antibody-drug conjugate (ADC) comprising a bispecific ERBB2 (HER2) antibody linked to auristatin, which delivers the cytotoxic agent to ERBB2 (HER2)-expressing cells, potentially resulting in cell growth inhibition and tumor regression (Cancer Res 2019;79(4 Suppl):Abstract nr P6-17-13). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|